BioElectron Technology Corp., a Mountain View, California-based biotech company, raised $40 million in debt financing.
Solar Capital Partners and its affiliates provided the financing.
The company will use the funds to support activities related to its continued development and planned commercial launch of EPI-743, a pre-NDA state compound that targets inherited mitochondrial disease and the advancement of its existing clinical and pre-clinical pipeline of redox therapeutics.
Led by Dr. Matthew Klein, CEO, BioElectron is advancing EPI-743, a pre-NDA stage compound for the treatment of inherited mitochondrial disease as well as EPI-589, being developed for the treatment of adult neurodegenerative diseases.
The company has also developed a discovery platform that leverages its expertise in the chemistry of a specific set of enzymes—oxidoreductases—critical to the regulation of inflammation, oxidative stress, and ferroptosis. This discovery platform has yielded a rich pre-clinical pipeline of molecules targeting pathways critical to central nervous system disease pathology and systemic inflammatory disorders.
To date, BioElectron’s discovery and clinical development efforts have been supported through investments from private investors, venture capital groups, and patient foundations, as well as a strategic partnership with Sumitomo Dainippon Pharma Co., Ltd.